Your browser doesn't support javascript.
loading
CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.
Montaudié, Henri; Sormani, Laura; Dadone-Montaudié, Bérengère; Heim, Marjorie; Cardot-Leccia, Nathalie; Tulic, Meri K; Beranger, Guillaume; Gay, Anne-Sophie; Debayle, Delphine; Cheli, Yann; Raymond, Jérémy H; Sohier, Pierre; Petit, Valérie; Rocchi, Stéphane; Gesbert, Franck; Larue, Lionel; Passeron, Thierry.
Afiliação
  • Montaudié H; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France; D
  • Sormani L; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France.
  • Dadone-Montaudié B; Department of Pathology, Université Nice Côte d'Azur, Nice, France; Laboratory of Solid Tumors Genetics, Institute for Research on Cancer and Aging of Nice, CNRS UMR 7284/ Institut national de la santé et de la recherche médicale (INSERM) U1081, CHU Nice, Université Nice Côte d'Azur, Nice, France.
  • Heim M; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France.
  • Cardot-Leccia N; Department of Pathology, Université Nice Côte d'Azur, Nice, France.
  • Tulic MK; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France.
  • Beranger G; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France.
  • Gay AS; IPMC, CNRS, Université Côte d'Azur, Sophia Antipolis, France.
  • Debayle D; IPMC, CNRS, Université Côte d'Azur, Sophia Antipolis, France.
  • Cheli Y; Team 1, Biology and pathologies of melanocytes, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France.
  • Raymond JH; Normal and Pathological Development of Melanocytes, Institut Curie, Institut national de la santé et de la recherche médicale (INSERM) U1021, PSL Research University, Paris, France; UMR 3347, CNRS, Université Paris-Saclay, Paris, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France.
  • Sohier P; Normal and Pathological Development of Melanocytes, Institut Curie, Institut national de la santé et de la recherche médicale (INSERM) U1021, PSL Research University, Paris, France; UMR 3347, CNRS, Université Paris-Saclay, Paris, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France.
  • Petit V; Normal and Pathological Development of Melanocytes, Institut Curie, Institut national de la santé et de la recherche médicale (INSERM) U1021, PSL Research University, Paris, France; UMR 3347, CNRS, Université Paris-Saclay, Paris, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France.
  • Rocchi S; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France.
  • Gesbert F; Normal and Pathological Development of Melanocytes, Institut Curie, Institut national de la santé et de la recherche médicale (INSERM) U1021, PSL Research University, Paris, France; UMR 3347, CNRS, Université Paris-Saclay, Paris, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France.
  • Larue L; Normal and Pathological Development of Melanocytes, Institut Curie, Institut national de la santé et de la recherche médicale (INSERM) U1021, PSL Research University, Paris, France; UMR 3347, CNRS, Université Paris-Saclay, Paris, France; Equipe Labellisée Ligue Contre le Cancer, Paris, France.
  • Passeron T; Team 12, Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms, Centre Méditerranéen de Médecine Moléculaire (C3M), Institut national de la santé et de la recherche médicale (INSERM) U1065, Université Nice Côte d'Azur, Nice, France; D
J Invest Dermatol ; 142(2): 425-434, 2022 02.
Article em En | MEDLINE | ID: mdl-34310951
The potential role of CLEC12B, a gene predominantly expressed by skin melanocytes discovered through transcriptomic analysis, in melanoma is unknown. In this study, we show that CLEC12B expression is lower in melanoma and melanoma metastases than in melanocytes and benign melanocytic lesions and that its decrease correlates with poor prognosis. We further show that CLEC12B recruits SHP2 phosphatase through its immunoreceptor tyrosine-based inhibition motif domain, inactivates signal transducer and activator of transcription 1/3/5, increases p53/p21/p27 expression/activity, and modulates melanoma cell proliferation. The growth of human melanoma cells overexpressing CLEC12B in nude mice after subcutaneous injection is significantly decreased compared with that in the vehicle control group and is associated with decreased signal transducer and activator of transcription 3 phosphorylation and increased p53 levels in the tumors. Reducing the level of CLEC12B had the opposite effect. We show that CLEC12B represses the activation of the signal transducer and activator of transcription pathway and negatively regulates the cell cycle, providing a proliferative asset to melanoma cells.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Receptores Mitogênicos / Lectinas Tipo C / Fator de Transcrição STAT3 / Proteína Tirosina Fosfatase não Receptora Tipo 11 / Melanoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Receptores Mitogênicos / Lectinas Tipo C / Fator de Transcrição STAT3 / Proteína Tirosina Fosfatase não Receptora Tipo 11 / Melanoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article